Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC4 | P56524 | 18/20 | 0.53 |
| ▸ | HDAC6 | Q9UBN7 | 10/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.46 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29381550 | 0.88 | KDM4E (0.57) | HDAC4HDAC6KDM4EPOLBHDAC8 | |
| Bromide SCHEMBL22530932 | 0.87 | KDM4E (0.56) | HDAC4HDAC6KDM4EPOLBHDAC8 | |
| SCHEMBL21001692 | 0.86 | KDM4E (0.54) | KDM4EPOLB | |
| SCHEMBL29381830 | 0.84 | HDAC4 (0.57) | HDAC4HDAC6HDAC8HDAC1HDAC5 | |
| SCHEMBL21033311 | 0.84 | HDAC4 (0.50) | HDAC4HDAC6HDAC8HDAC2 | |
| SCHEMBL29382012 | 0.83 | HDAC6 (0.50) | HDAC4HDAC6HDAC8HDAC1HDAC2 | |
| SCHEMBL21033486 | 0.83 | KDM4E (0.50) | KDM4EPOLB | |
| SCHEMBL21033484 | 0.83 | KDM4E (0.50) | KDM4EPOLB | |
| SCHEMBL29381493 | 0.82 | HDAC4 (0.65) | HDAC4HDAC6HDAC1 | |
| SCHEMBL29381942 | 0.82 | HDAC4 (0.65) | HDAC4HDAC6HDAC8HDAC1HDAC5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3953353-A1 | NOVEL OXADIAZOLE COMPOUNDS FOR CONTROLLING OR PREVENTING PHYTOPATHOGENIC FUNGI | PI Industries Ltd. (IN) | 2022-02-16 | — | — | EP | claimed |
| US-20220151236-A1 | NOVEL OXADIAZOLE COMPOUNDS FOR CONTROLLING OR PREVENTING PHYTOPATHOGENIC FUNGI | PI INDUSTRIES LTD. (IN) | 2022-05-19 | — | — | US | disclosed |
| EP-3953353-A1 | NOVEL OXADIAZOLE COMPOUNDS FOR CONTROLLING OR PREVENTING PHYTOPATHOGENIC FUNGI | PI Industries Ltd. (IN) | 2022-02-16 | — | — | EP | disclosed |
| US-20210371431-A1 | HETEROCYCLIC COMPOUNDS AS PRMT5 INHIBITORS | JUBILANT EPISCRIBE LLC | 2021-12-02 | — | — | US | disclosed |
| WO-2020208510-A1 | NOVEL OXADIAZOLE COMPOUNDS FOR CONTROLLING OR PREVENTING PHYTOPATHOGENIC FUNGI | PI INDUSTRIES LIMITED (IN) | 2020-10-15 | — | — | WO | disclosed |
| WO-2019102494-A1 | HETEROCYCLIC COMPOUNDS AS PRMT5 INHIBITORS | JUBILANT BIOSYS LIMITED (IN) | 2019-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220151236-A1 | NOVEL OXADIAZOLE COMPOUNDS FOR CONTROLLING OR PREVENTING PHYTOPATHOGENIC FUNGI | OXA1L, ERG28, CYP51A1 | HDAC4 2778/4885HDAC6 1290/4885KDM4E 1507/4885 |
| US-20210371431-A1 | HETEROCYCLIC COMPOUNDS AS PRMT5 INHIBITORS | PRMT5, PRMT1, PRMT3 | HDAC4 402/4885HDAC6 319/4885KDM4E 221/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.